Information Provided By:
Fly News Breaks for March 15, 2019
KPTI
Mar 15, 2019 | 08:39 EDT
Wedbush analyst David Nierengarten maintained an Outperform rating and $6 price target on Karyopharm. In a note titled "FDA Extends PDUFA by Three Months," he said he is inclined to view the extension as a positive for the company "given the negative sentiment on the name and general belief that an April 6, 2019 approval was unlikely."
News For KPTI From the Last 2 Days
There are no results for your query KPTI